{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=one+stage+exchange",
    "query": {
      "intervention": "one stage exchange"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=one+stage+exchange&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T04:26:34.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01918306",
      "title": "GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative Breast Cancer",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Triple Negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "GDC -0941",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01918306"
    },
    {
      "nct_id": "NCT01712880",
      "title": "Treatment of Acute Periprosthetic Total Hip Arthroplasty Infections",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Periprosthetic Infection Total Hip Arthoplasty"
      ],
      "interventions": [
        {
          "name": "open debridement with modular exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "one stage exchange",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "OrthoCarolina Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-10",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-06",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712880"
    },
    {
      "nct_id": "NCT02734134",
      "title": "One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "One-stage exchange joint replacement surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Two-stage exchange joint replacement surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "OrthoCarolina Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2016-05-18",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • New York, New York • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734134"
    },
    {
      "nct_id": "NCT04108156",
      "title": "A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "PDS Implant Pre-Filled with 100 mg/mL Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Ranibizumab 0.5 mg Injection",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab refill exchange",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 672,
      "start_date": "2019-09-30",
      "completion_date": "2027-07-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 88,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04108156"
    },
    {
      "nct_id": "NCT02898688",
      "title": "P3+ Intervention Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccination"
      ],
      "interventions": [
        {
          "name": "Control Site",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intervention Site",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient-level Control Group",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient-level Intervention Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 2200,
      "start_date": "2017-06-12",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 23,
      "location_summary": "Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02898688"
    },
    {
      "nct_id": "NCT02950480",
      "title": "Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "zafirlukast",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (no intervention)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2017-03-13",
      "completion_date": "2018-12-20",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02950480"
    },
    {
      "nct_id": "NCT05679401",
      "title": "A Study With Imlifidase in Anti-GBM Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anti-Glomerular Basement Membrane Disease",
        "Anti-Glomerular Basement Membrane Antibody Disease",
        "Goodpasture Syndrome",
        "Good Pasture Syndrome"
      ],
      "interventions": [
        {
          "name": "Imlifidase",
          "type": "DRUG"
        },
        {
          "name": "Plasma exchange (PLEX)",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide (CYC)",
          "type": "DRUG"
        },
        {
          "name": "Glucocorticoids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hansa Biopharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-12-22",
      "completion_date": "2026-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05679401"
    },
    {
      "nct_id": "NCT00742417",
      "title": "Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Albutein 5%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 42,
      "start_date": "2007-07",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-14",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Whiting, New Jersey",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Whiting",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00742417"
    },
    {
      "nct_id": "NCT01524068",
      "title": "A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Standard Steroid Treatment",
          "type": "DRUG"
        },
        {
          "name": "The Standard Steroid Treatment, Plasma Exchange and rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-09",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-01-05",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 5,
      "location_summary": "Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        },
        {
          "city": "Philladelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524068"
    },
    {
      "nct_id": "NCT04935177",
      "title": "Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplantation in Highly Sensitized Patients"
      ],
      "interventions": [
        {
          "name": "Imlifidase",
          "type": "DRUG"
        },
        {
          "name": "PLEX",
          "type": "PROCEDURE"
        },
        {
          "name": "IVIg",
          "type": "DRUG"
        },
        {
          "name": "Anti-CD20 antibodies",
          "type": "DRUG"
        },
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Remain on wait list",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Hansa Biopharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-10-14",
      "completion_date": "2025-06-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-08T04:26:34.606Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04935177"
    }
  ]
}